{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:48Z","timestamp":1787628108666,"version":"build-2736575974"},"reference-count":49,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2173466","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T15:51:31Z","timestamp":1674834691000},"page":"243-253","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed\/refractory multiple myeloma patients in Canada and France"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-1865","authenticated-orcid":false,"given":"Korinna","family":"Karampampa","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-2821","authenticated-orcid":false,"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Precision Health, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4081-225X","authenticated-orcid":false,"given":"Meena","family":"Venkatachalam","sequence":"additional","affiliation":[{"name":"Precision Health, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-4552","authenticated-orcid":false,"given":"Francois-Emery","family":"Cotte","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Rueil-Malmaison, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3618-6962","authenticated-orcid":false,"given":"Devender","family":"Dhanda","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_5_4_1","volume-title":"ABECMA (idecabtagene vicleucel) [prescribing information]","author":"Celgene","year":"2021","unstructured":"Celgene. ABECMA (idecabtagene vicleucel) [prescribing information]. Summit, NJ: Celgene Corporation, a Bristol-Myers Squibb Company; 2021."},{"key":"e_1_3_5_5_1","volume-title":"Abecma (idecabtagene vicleucel) [summary of product characteristics]","author":"Celgene","year":"2021","unstructured":"Celgene. Abecma (idecabtagene vicleucel) [summary of product characteristics]. Utrecht, Netherlands: Celgene Europe B.V; 2021."},{"key":"e_1_3_5_6_1","unstructured":"Bristol Myers Squibb. Health Canada approves ABECMATM (idecabtagene vicleucel) the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma. 2021. Available from: https:\/\/www.bms.com\/ca\/en\/media\/press-release-listing\/2021-05-31-press-release.html#:\u223c:text=Health%20Canada%20Approves%20ABECMATM Relapsed%20and%20Refractory%20Multiple%20Myeloma&text=%E2%80%9CToday\u2019s%20approval%20is%20an%20important i. n%20Canada%2C%E2%80%9D%20says%20Dr.Pu."},{"key":"e_1_3_5_7_1","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb receives approval for Abecma (idecabtagene vicleucel) the first CAR T therapy approved for the treatment of multiple myeloma in Japan; 2022. Available from: https:\/\/news.bms.com\/news\/details\/2022\/Bristol-Myers-Squibb-Receives-Approval-for-Abecma-idecabtagene-vicleucel-the-First-CAR-T-Therapy-Approved-for-the-Treatment-of-Multiple-Myeloma-in-Japan\/default.aspx."},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225606"},{"key":"e_1_3_5_9_1","unstructured":"National Institute for Health Care and Excellence [INTERNET]. Panobinostat for treating multiple myeloma after at least 2 previous treatments [TA 380]; 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta380."},{"key":"e_1_3_5_10_1","unstructured":"National Institute for Health Care and Excellence [INTERNET]. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma: technology appraisal guidance [TA510]; 2018. Available from: https:\/\/www.nice.org.uk\/guidance\/ta510."},{"key":"e_1_3_5_11_1","unstructured":"National Institute for Health Care and Excellence [INTERNET]. Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib [TA 427]; 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta427."},{"key":"e_1_3_5_12_1","unstructured":"National Institute for Health Care and Excellence [INTERNET]. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [TA505]; 2018. Availalble from: https:\/\/www.nice.org.uk\/guidance\/ta505\/."},{"issue":"9","key":"e_1_3_5_13_1","first-page":"1315","article-title":"Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma","volume":"27","author":"Beinfeld M","year":"2021","unstructured":"Beinfeld M, Lee S, McQueen B, et\u00a0al. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma. J Manag Care Spec Pharm. 2021;27(9):1315\u20131320.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"e_1_3_5_14_1","first-page":"S17","article-title":"OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa","volume":"21","author":"Anderson LD","year":"2021","unstructured":"Anderson LD, Shah N, Jagannath S, et\u00a0al. OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 2):S17\u2013S18.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00507-2"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1188\/20.CJON.538-546"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.472"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13950"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-0157"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0314-5"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-643320"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563759"},{"key":"e_1_3_5_25_1","article-title":"CADTH reimbursement review: idecabtagene vicleucel (Abecma)","author":"Canadian Agency for Drugs and Technologies in Health [INTERNET].","year":"2022","unstructured":"Canadian Agency for Drugs and Technologies in Health [INTERNET]. CADTH reimbursement review: idecabtagene vicleucel (Abecma): Canadian Journal of Health Technologies; 2022. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/PG0240-Abecma.pdf","journal-title":"Canadian Journal of Health Technologies;"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28020119"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13298"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.25318\/1410006001-eng"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112080"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_5_31_1","unstructured":"European Medicines Agency [INTERNET]. CARVYKTI (Ciltacabtagene Autoleucel) Summary of product characteristics; 2022. Avaialble from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005913"},{"key":"e_1_3_5_33_1","unstructured":"Institute for Clinical and Economic Review [INTERNET]. Anti b-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma. 2021. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Multiple-Myeloma_Final-Report_Update_070921.pdf."},{"key":"e_1_3_5_34_1","unstructured":"Canadian Agency for Drugs and Technologies in Health [INTERNET]. Pan-canadian oncology drug review registered clinician feedback on a pCODR expert review committee initial recommendation pomalidomide (Pomalyst) for multiple myeloma; 2014. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-pomalyst-mm-fn-egr.pdf."},{"key":"e_1_3_5_35_1","unstructured":"Scottish Medicines Consortium [INTERNET]. Daratumumab (Darzalex). Advice. SMC1205\/17; 2017. Available from: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/daratumumab-darzalex-resubmission-120517\/."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.08.010"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.05.012"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1529674"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.06.011"},{"key":"e_1_3_5_40_1","unstructured":"Ontario Case Costing Initiative. 2019. https:\/\/data.ontario.ca\/dataset\/ontario-case-costing-initiative-occi."},{"key":"e_1_3_5_41_1","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review Registered Clinician Feedback on a pCODR Expert Review Committee Initial Recommendation Daratumumab (Darzalex) for Multiple Myeloma. 2017. https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf."},{"key":"e_1_3_5_42_1","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review Final Economic Guidance Report Bortezomib (Velcade) for Multiple Myeloma. 2013. https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-velcademm-fn-egr.pdf."},{"key":"e_1_3_5_43_1","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review Final Economic Guidance Report Carfilzomib (Kyprolis) for Multiple Myeloma. 2017. https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_carfilzomib_kyprolis_mm_rel_fn_egr.pdf."},{"key":"e_1_3_5_44_1","unstructured":"Ontario Drug Benefit Formulary. https:\/\/www.formulary.health.gov.on.ca\/formulary\/."},{"key":"e_1_3_5_45_1","unstructured":"Aide au Codage. https:\/\/www.aideaucodage.fr\/ccam."},{"key":"e_1_3_5_46_1","unstructured":"Canadian Institute for Health Information. Cost of a Standard Hospital Stay. https:\/\/yourhealthsystem.cihi.ca\/hsp\/inbrief.#!\/indicators\/015\/cost-of-a-standard-hospital-stay\/;mapC1;mapLevel2;\/."},{"key":"e_1_3_5_47_1","unstructured":"Ontario Health Insurance Plan. Schedule of Benefits for Laboratory Services 2020. https:\/\/health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/lab\/lab_mn2020.pdf."},{"key":"e_1_3_5_48_1","unstructured":"Autorit\u00e9 de Sant\u00e9 H. Rapport d\u2018activit\u00e9. 2015. [Internet]. Disponible sur: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2016-07\/rapport_activite_2015.pdf."},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1421546"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2835-7"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2173466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T09:56:06Z","timestamp":1701942966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2173466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2173466"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2173466","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}